Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{0c848c9f4f67423eaaf0f555ed415902,
title = "Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile",
abstract = "Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder with estimated global prevalence rates between 3{\%} and 5{\%} in children and 2.5{\%} in adults, depending on the classification system used. The psychostimulant methylphenidate is one of the most frequently used medications for ADHD. In this analysis article we describe shortly the evidence in the field, an application for inclusion of methylphenidate on the WHO Model List of Essential Medicines, the comments raised to the application and the WHO Expert Committee's decision. The application of getting methylphenidate on the WHO list was overzealous in reporting potential benefits, without highlighting key uncertainties and harms. Decisions encompassing medicines candidate to the WHO Model List should not be based on speculation about potential benefits and should fully incorporate areas of uncertainties. Even though methylphenidate has been used for over 60 years, the evidence concerning the benefits of this medication in children, adolescents and adults with ADHD is uncertain. The decision of the committee was to not include methylphenidate in the WHO Model List of Essential Medicines 'due to uncertainties in the estimates of benefit, and concerns regarding the quality and limitations of the available evidence for both benefit and harm'.",
keywords = "adult psychiatry, child & adolescent psychiatry, psychiatry",
author = "Storeb{\o}, {Ole Jakob} and Christian Gluud",
note = "{\circledC} Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.",
year = "2020",
month = "4",
day = "24",
doi = "10.1136/bmjebm-2019-111328",
language = "English",
journal = "Evidence-Based Medicine",
issn = "1356-5524",
publisher = "B M J Group",

}

RIS

TY - JOUR

T1 - Methylphenidate for ADHD rejected from the WHO Essential Medicines List due to uncertainties in benefit-harm profile

AU - Storebø, Ole Jakob

AU - Gluud, Christian

N1 - © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

PY - 2020/4/24

Y1 - 2020/4/24

N2 - Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder with estimated global prevalence rates between 3% and 5% in children and 2.5% in adults, depending on the classification system used. The psychostimulant methylphenidate is one of the most frequently used medications for ADHD. In this analysis article we describe shortly the evidence in the field, an application for inclusion of methylphenidate on the WHO Model List of Essential Medicines, the comments raised to the application and the WHO Expert Committee's decision. The application of getting methylphenidate on the WHO list was overzealous in reporting potential benefits, without highlighting key uncertainties and harms. Decisions encompassing medicines candidate to the WHO Model List should not be based on speculation about potential benefits and should fully incorporate areas of uncertainties. Even though methylphenidate has been used for over 60 years, the evidence concerning the benefits of this medication in children, adolescents and adults with ADHD is uncertain. The decision of the committee was to not include methylphenidate in the WHO Model List of Essential Medicines 'due to uncertainties in the estimates of benefit, and concerns regarding the quality and limitations of the available evidence for both benefit and harm'.

AB - Attention deficit hyperactivity disorder (ADHD) is a common psychiatric disorder with estimated global prevalence rates between 3% and 5% in children and 2.5% in adults, depending on the classification system used. The psychostimulant methylphenidate is one of the most frequently used medications for ADHD. In this analysis article we describe shortly the evidence in the field, an application for inclusion of methylphenidate on the WHO Model List of Essential Medicines, the comments raised to the application and the WHO Expert Committee's decision. The application of getting methylphenidate on the WHO list was overzealous in reporting potential benefits, without highlighting key uncertainties and harms. Decisions encompassing medicines candidate to the WHO Model List should not be based on speculation about potential benefits and should fully incorporate areas of uncertainties. Even though methylphenidate has been used for over 60 years, the evidence concerning the benefits of this medication in children, adolescents and adults with ADHD is uncertain. The decision of the committee was to not include methylphenidate in the WHO Model List of Essential Medicines 'due to uncertainties in the estimates of benefit, and concerns regarding the quality and limitations of the available evidence for both benefit and harm'.

KW - adult psychiatry

KW - child & adolescent psychiatry

KW - psychiatry

U2 - 10.1136/bmjebm-2019-111328

DO - 10.1136/bmjebm-2019-111328

M3 - Journal article

JO - Evidence-Based Medicine

JF - Evidence-Based Medicine

SN - 1356-5524

ER -

ID: 59736352